GlobeNewswire Inc | Nov 10, 2020 08:47AM EST

November 10, 2020

LYON, France,November 10, 2020--EDAP TMS SA(Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that management will be presenting at the Jefferies Virtual London Healthcare Conference, which is being heldNovember 17-19, 2020.

Presentation Details Date:Tuesday, November 17 Time:10:00am BT Webcast: https://wsw.com/webcast/jeff141/edap/1815450

The webcast will be archived and available for replay for a period of 90 days.

AboutEDAP TMS SA

A recognized leader in the global therapeutic ultrasound market,EDAP TMSdevelops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices,EDAP TMSintroduced the Focal One inEuropeand in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment such as the Sonolith i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.

Forward-Looking StatementsIn addition to historical information, this press release contains forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the sustained activity of our lithotripsy business, as well as the length and severity of the recent COVID-19 outbreak, including its impacts across our businesses on demand for our devices and services. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with theSecurities and Exchange Commissionand in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.

Company Contact Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 50bconfort@edap-tms.com

Investor Contact Jeremy Feffer LifeSci Advisors, LLC 212-915-2568jeremy@lifesciadvisors.com